FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059453816> ?p ?o ?g. }

• W2059453816 endingPage "147" @default.
• W2059453816 startingPage "143" @default.
• W2059453816 abstract "IntroductionPatients with stage III non–small-cell lung cancer and poor performance status and/or weight loss do not seem to benefit from standard therapy. Based on the preclinical interaction between epidermal growth factor receptor inhibitors and radiation, we designed a trial of induction chemotherapy followed by thoracic radiotherapy and concurrent erlotinib.MethodsPatients with poor-risk unresectable stage III non–small-cell lung cancer received two cycles of carboplatin at an AUC of 5 and nab-paclitaxel at 100 mg/m2 on days 1 and 8 every 21 days, followed by erlotinib administered concurrently with thoracic radiotherapy. Maintenance was not permitted. Molecular analysis was performed in available specimens. Seventy-two eligible patients were required to test whether the 1-year survival rate was less than 50% or greater than or equal to 65% with approximately 90% power at a significance level of 0.10.ResultsFrom March 2008 to October 2011, 78 patients were enrolled, three of whom were ineligible. The median age was 68 (range, 39–88) and 32% were aged greater than or equal to 75 years. Patients were evenly distributed between stages IIIA and IIIB and the majority had performance status 2. The overall response rate was 67% and the disease control rate was 93%. Treatment was well tolerated. The median PFS and OS were 11 and 17 months, respectively. The overall 12-month OS was 57%, which narrowly missed the prespecified target for significance.ConclusionsPatients with poor-risk stage III non–small-cell lung cancer had better than expected outcomes with a regimen of induction carboplatin/nab-paclitaxel followed by thoracic radiotherapy and erlotinib. However, as per the statistical design, the 12-month OS was not sufficiently high to warrant further studies." @default.
• W2059453816 created "2016-06-24" @default.
• W2059453816 creator A5002507883 @default.
• W2059453816 creator A5028702225 @default.
• W2059453816 creator A5044788596 @default.
• W2059453816 creator A5048675362 @default.
• W2059453816 creator A5048914302 @default.
• W2059453816 creator A5057437860 @default.
• W2059453816 creator A5063904421 @default.
• W2059453816 creator A5071796883 @default.
• W2059453816 creator A5077185466 @default.
• W2059453816 creator A5083466962 @default.
• W2059453816 creator A5087107933 @default.
• W2059453816 date "2015-01-01" @default.
• W2059453816 modified "2023-10-17" @default.
• W2059453816 title "A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)" @default.
• W2059453816 cites W1980127383 @default.
• W2059453816 cites W1995805135 @default.
• W2059453816 cites W2068669225 @default.
• W2059453816 cites W2151164486 @default.
• W2059453816 cites W2153865661 @default.
• W2059453816 doi "https://doi.org/10.1097/jto.0000000000000347" @default.
• W2059453816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4320012" @default.
• W2059453816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25384173" @default.
• W2059453816 hasPublicationYear "2015" @default.
• W2059453816 type Work @default.
• W2059453816 sameAs 2059453816 @default.
• W2059453816 citedByCount "44" @default.
• W2059453816 countsByYear W20594538162015 @default.
• W2059453816 countsByYear W20594538162016 @default.
• W2059453816 countsByYear W20594538162017 @default.
• W2059453816 countsByYear W20594538162018 @default.
• W2059453816 countsByYear W20594538162019 @default.
• W2059453816 countsByYear W20594538162020 @default.
• W2059453816 countsByYear W20594538162021 @default.
• W2059453816 countsByYear W20594538162022 @default.
• W2059453816 countsByYear W20594538162023 @default.
• W2059453816 crossrefType "journal-article" @default.
• W2059453816 hasAuthorship W2059453816A5002507883 @default.
• W2059453816 hasAuthorship W2059453816A5028702225 @default.
• W2059453816 hasAuthorship W2059453816A5044788596 @default.
• W2059453816 hasAuthorship W2059453816A5048675362 @default.
• W2059453816 hasAuthorship W2059453816A5048914302 @default.
• W2059453816 hasAuthorship W2059453816A5057437860 @default.
• W2059453816 hasAuthorship W2059453816A5063904421 @default.
• W2059453816 hasAuthorship W2059453816A5071796883 @default.
• W2059453816 hasAuthorship W2059453816A5077185466 @default.
• W2059453816 hasAuthorship W2059453816A5083466962 @default.
• W2059453816 hasAuthorship W2059453816A5087107933 @default.
• W2059453816 hasBestOaLocation W20594538161 @default.
• W2059453816 hasConcept C121608353 @default.
• W2059453816 hasConcept C126322002 @default.
• W2059453816 hasConcept C143998085 @default.
• W2059453816 hasConcept C146357865 @default.
• W2059453816 hasConcept C151730666 @default.
• W2059453816 hasConcept C2776256026 @default.
• W2059453816 hasConcept C2776611710 @default.
• W2059453816 hasConcept C2776694085 @default.
• W2059453816 hasConcept C2776907518 @default.
• W2059453816 hasConcept C2778087573 @default.
• W2059453816 hasConcept C2778239845 @default.
• W2059453816 hasConcept C2779438470 @default.
• W2059453816 hasConcept C2781413609 @default.
• W2059453816 hasConcept C2781451048 @default.
• W2059453816 hasConcept C509974204 @default.
• W2059453816 hasConcept C71924100 @default.
• W2059453816 hasConcept C86803240 @default.
• W2059453816 hasConcept C90924648 @default.
• W2059453816 hasConceptScore W2059453816C121608353 @default.
• W2059453816 hasConceptScore W2059453816C126322002 @default.
• W2059453816 hasConceptScore W2059453816C143998085 @default.
• W2059453816 hasConceptScore W2059453816C146357865 @default.
• W2059453816 hasConceptScore W2059453816C151730666 @default.
• W2059453816 hasConceptScore W2059453816C2776256026 @default.
• W2059453816 hasConceptScore W2059453816C2776611710 @default.
• W2059453816 hasConceptScore W2059453816C2776694085 @default.
• W2059453816 hasConceptScore W2059453816C2776907518 @default.
• W2059453816 hasConceptScore W2059453816C2778087573 @default.
• W2059453816 hasConceptScore W2059453816C2778239845 @default.
• W2059453816 hasConceptScore W2059453816C2779438470 @default.
• W2059453816 hasConceptScore W2059453816C2781413609 @default.
• W2059453816 hasConceptScore W2059453816C2781451048 @default.
• W2059453816 hasConceptScore W2059453816C509974204 @default.
• W2059453816 hasConceptScore W2059453816C71924100 @default.
• W2059453816 hasConceptScore W2059453816C86803240 @default.
• W2059453816 hasConceptScore W2059453816C90924648 @default.
• W2059453816 hasIssue "1" @default.
• W2059453816 hasLocation W20594538161 @default.
• W2059453816 hasLocation W20594538162 @default.
• W2059453816 hasLocation W20594538163 @default.
• W2059453816 hasOpenAccess W2059453816 @default.
• W2059453816 hasPrimaryLocation W20594538161 @default.
• W2059453816 hasRelatedWork W1994763147 @default.
• W2059453816 hasRelatedWork W2023597833 @default.
• W2059453816 hasRelatedWork W2035762060 @default.
• W2059453816 hasRelatedWork W2103997800 @default.
• W2059453816 hasRelatedWork W2120992361 @default.
• W2059453816 hasRelatedWork W2168841302 @default.

• next